We speculate that irbesartan blocked the effects of STZ-induced prediabetes by inhibiting Ang II and AT1R, and thus reducing the activation of the p38MAPK and caspase-3 pathways, ultimately improving pancreatic β-cell function in the acute prediabetic stage. This evidence concerns the gene AGTR1 and prediabetes syndrome.